Tags

Type your tag names separated by a space and hit enter

Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
Mov Disord. 2005 Jun; 20(6):680-6.MD

Abstract

Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K(+) channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement < 3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects.

Authors+Show Affiliations

Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

15719424

Citation

Liu, Zhi, et al. "Mosapride Citrate, a Novel 5-HT4 Agonist and Partial 5-HT3 Antagonist, Ameliorates Constipation in Parkinsonian Patients." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 20, no. 6, 2005, pp. 680-6.
Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord. 2005;20(6):680-6.
Liu, Z., Sakakibara, R., Odaka, T., Uchiyama, T., Uchiyama, T., Yamamoto, T., Ito, T., Asahina, M., Yamaguchi, K., Yamaguchi, T., & Hattori, T. (2005). Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Movement Disorders : Official Journal of the Movement Disorder Society, 20(6), 680-6.
Liu Z, et al. Mosapride Citrate, a Novel 5-HT4 Agonist and Partial 5-HT3 Antagonist, Ameliorates Constipation in Parkinsonian Patients. Mov Disord. 2005;20(6):680-6. PubMed PMID: 15719424.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. AU - Liu,Zhi, AU - Sakakibara,Ryuji, AU - Odaka,Takeo, AU - Uchiyama,Tomoyuki, AU - Uchiyama,Tomoyuki, AU - Yamamoto,Tatsuya, AU - Ito,Takashi, AU - Asahina,Masato, AU - Yamaguchi,Kazuya, AU - Yamaguchi,Taketo, AU - Hattori,Takamichi, PY - 2005/2/19/pubmed PY - 2005/7/30/medline PY - 2005/2/19/entrez SP - 680 EP - 6 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov. Disord. VL - 20 IS - 6 N2 - Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K(+) channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement < 3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/15719424/Mosapride_citrate_a_novel_5_HT4_agonist_and_partial_5_HT3_antagonist_ameliorates_constipation_in_parkinsonian_patients_ L2 - https://doi.org/10.1002/mds.20387 DB - PRIME DP - Unbound Medicine ER -